BIIB

Biogen Inc (BIIB) | Rumor.io

Biogen

BIIB

Attention (50-day avg)0%

Attention rank (50-day avg)#968

Bullish sentiment (50-day avg)79%

Price to earnings ratio40.7

Market capitalization33.8B

Earnings per share5.62

Dividend yield (TTM)—

Revenue (annual)9.9B

Net income (annual)1.3B

Social

What share of all stock conversation is about BIIB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% 0	0% 0	0% -0.01

Aug 25

Biogen is committing to deploy Veeva Vault CRM globally as its commercial platform, following Regeneron's lead.
Biogen's ACD-20 royalty deal with Genentech could be impacted if the company's stock price were to drop below a certain threshold.
Biogen's stock price has reached a new 52-week high.

Generated by AI

Sentiment

Of the messages about BIIB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +46.39	85.55% -12.4
Bearish	—	—	0% -46.39	14.45% +12.4

Bullish· Mar 31

Biogen's acquisition of Apellis is expected to add significant revenue, with Syfovre generating $587M in 2025 revenue and Empaveli doing more than $100M.
The deal is accretive to non-GAAP EPS from 2027, with the combined 2025 net product revenue expected to be $689M, growing at mid-to-high teens through 2028.
The acquisition is expected to boost Biogen's growth outlook, accelerate expansion into nephrology, and enhance the company's growth portfolio in immunology and rare disease.

Bearish· Feb 13

$BIIB's Leqembi sales for Alzheimer's disease are weak, with one post stating "practically squat!" and another that it's so bad Biogen can't even spell it out clearly in earnings.
Biogen's stock is falling due to earnings and revenue misses, with one post stating that the company's revenue and profit shrink on Aduhelm costs and slumping sales of multiple sclerosis therapies.
Biogen's 2024 sales are expected to decline by a low to mid-single digit percentage compared to last year, with one post stating that the company's guidance is soft and the stock is selling off.

Generated by AI

Topics

Of the messages about BIIB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	55.56%	56.7%	58.35%
Analysts	—	33.33%	28.35%	14.2%
Technical Analysis	—	11.11%	1.03%	18.5%
Macro	—	0%	12.37%	4.55%
Earnings	—	0%	0%	3.63%
Controversies	—	0%	1.55%	0.77%

Earnings· Jul 29

Biogen's Q2 2026 revenue of $2.74B beat estimates, with growth portfolio revenue up 24% YoY.
The company's adjusted EPS of $3.60 also beat estimates, but was down 34% YoY due to higher expenses.
Biogen cut its FY26 adjusted EPS guidance to $12-$13, citing acquisition costs, but raised its revenue guidance for the year.

Analysts· Aug 7

Wells Fargo maintained an Overweight rating on Biogen Inc. (BIIB) and lowered its price target to $343.
Multiple analysts, including RBC, Baird, Wedbush, BofA, Oppenheimer, and Piper Sandler, lowered their price targets for Biogen Inc. (BIIB) to various levels between $269 and $354.
J.P. Morgan maintained a Hold rating on Biogen Inc. (BIIB) with no price target change.

Announcements· Jun 18

Biogen is acquiring RayThera Inc. for up to $1 billion, expanding its immunology pipeline with multiple anti-inflammatory assets.
The lead candidate from the acquisition is expected to enter Phase 1 development in Q3 2026, providing a near-term catalyst for the company.
The deal is mostly milestone-based, with the majority of the payment tied to clinical and regulatory milestones, giving Biogen a potential upside from the acquisition.

Controversies· Sep 27

Biogen Inc. ($BIIB) has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs.
The U.S. Department of Justice said Biogen agreed to pay $900M to resolve allegations that it paid kickbacks to physicians to prescribe its drugs.
Biogen has agreed to pay $900 million to settle allegations that it paid kickbacks to doctors between 2009 and March 2014 to induce them to prescribe the company’s drugs.

Technical Analysis· Sep 29

$BIIB has been rejected at the 200-day moving average going down.
The stock is predicted to drop under $270, with a possible stop loss raid down to $264.
$BIIB is in a strong short-term bullish trend, with a long-term bullish flip from bearish, and volume is trending up with low volatility.

Generated by AI

Community

Of the messages about BIIB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	4.5%	42.77%	60.42%
Newcomers	—	95.5%	57.23%	39.58%

Regulars· Jul 29

Biogen's Q2 2026 revenue of $2.74B beat estimates, with a 3% YoY increase, and growth portfolio revenue of $1.06B rising 24% YoY.
The company's adjusted EPS of $3.60 was lower than the previous year, due to higher expenses, but still beat estimates.
Biogen's CEO noted that the company has what it needs to grow, and is easing off acquisitions for a while, focusing on its growth portfolio.

Newcomers· May 18

The newcomer is primarily focused on NovaRed Mining, highlighting stronger copper grades and limited historical exploration, which has changed their view on the asset.
The newcomer is impressed by the strong revenue numbers and growth of $NXXT, with a yearly revenue of 81.8M and +195% yearly growth, making it a bullish setup.
The newcomer is discussing Biogen's success with Leqembi Alzheimer's, with Goldman Sachs raising Biogen's stock target, and mentioning the asset's recent rough stretch.

Generated by AI

News

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

1d agoYahoo Finance

How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data

Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...

6d agoYahoo Finance

Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?

Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...

7d agoYahoo Finance

Also Discussed

Investors talking about BIIB also mention

#	Name	Attention
1	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
2	Gilead Sciences, Inc.GILD	0%-0.04
3	Ionis Pharmaceuticals, Inc.IONS	0%new
4	Amgen Inc.AMGN	0.01%+0
5	Alnylam Pharmaceuticals, Inc.ALNY	0%0
6	Novartis AG Sponsored ADRNVS	0%-0.01
7	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
8	SAGE - Sage Therapeutics, Inc.	——
9	iShares Biotechnology ETFIBB	0.01%0
10	Alkermes plcALKS	0%0

Biogen Inc

Healthcare
Drug Manufacturers - General

Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.

Website

Location

225 Binney Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about BIIB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% 0	0% 0	0% -0.01

Aug 25

Biogen is committing to deploy Veeva Vault CRM globally as its commercial platform, following Regeneron's lead.
Biogen's ACD-20 royalty deal with Genentech could be impacted if the company's stock price were to drop below a certain threshold.
Biogen's stock price has reached a new 52-week high.

Generated by AI

Sentiment

Of the messages about BIIB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +46.39	85.55% -12.4
Bearish	—	—	0% -46.39	14.45% +12.4

Bullish· Mar 31

Biogen's acquisition of Apellis is expected to add significant revenue, with Syfovre generating $587M in 2025 revenue and Empaveli doing more than $100M.
The deal is accretive to non-GAAP EPS from 2027, with the combined 2025 net product revenue expected to be $689M, growing at mid-to-high teens through 2028.
The acquisition is expected to boost Biogen's growth outlook, accelerate expansion into nephrology, and enhance the company's growth portfolio in immunology and rare disease.

Bearish· Feb 13

$BIIB's Leqembi sales for Alzheimer's disease are weak, with one post stating "practically squat!" and another that it's so bad Biogen can't even spell it out clearly in earnings.
Biogen's stock is falling due to earnings and revenue misses, with one post stating that the company's revenue and profit shrink on Aduhelm costs and slumping sales of multiple sclerosis therapies.
Biogen's 2024 sales are expected to decline by a low to mid-single digit percentage compared to last year, with one post stating that the company's guidance is soft and the stock is selling off.

Generated by AI

Topics

Of the messages about BIIB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	55.56%	56.7%	58.35%
Analysts	—	33.33%	28.35%	14.2%
Technical Analysis	—	11.11%	1.03%	18.5%
Macro	—	0%	12.37%	4.55%
Earnings	—	0%	0%	3.63%
Controversies	—	0%	1.55%	0.77%

Earnings· Jul 29

Biogen's Q2 2026 revenue of $2.74B beat estimates, with growth portfolio revenue up 24% YoY.
The company's adjusted EPS of $3.60 also beat estimates, but was down 34% YoY due to higher expenses.
Biogen cut its FY26 adjusted EPS guidance to $12-$13, citing acquisition costs, but raised its revenue guidance for the year.

Analysts· Aug 7

Wells Fargo maintained an Overweight rating on Biogen Inc. (BIIB) and lowered its price target to $343.
Multiple analysts, including RBC, Baird, Wedbush, BofA, Oppenheimer, and Piper Sandler, lowered their price targets for Biogen Inc. (BIIB) to various levels between $269 and $354.
J.P. Morgan maintained a Hold rating on Biogen Inc. (BIIB) with no price target change.

Announcements· Jun 18

Biogen is acquiring RayThera Inc. for up to $1 billion, expanding its immunology pipeline with multiple anti-inflammatory assets.
The lead candidate from the acquisition is expected to enter Phase 1 development in Q3 2026, providing a near-term catalyst for the company.
The deal is mostly milestone-based, with the majority of the payment tied to clinical and regulatory milestones, giving Biogen a potential upside from the acquisition.

Controversies· Sep 27

Biogen Inc. ($BIIB) has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs.
The U.S. Department of Justice said Biogen agreed to pay $900M to resolve allegations that it paid kickbacks to physicians to prescribe its drugs.
Biogen has agreed to pay $900 million to settle allegations that it paid kickbacks to doctors between 2009 and March 2014 to induce them to prescribe the company’s drugs.

Technical Analysis· Sep 29

$BIIB has been rejected at the 200-day moving average going down.
The stock is predicted to drop under $270, with a possible stop loss raid down to $264.
$BIIB is in a strong short-term bullish trend, with a long-term bullish flip from bearish, and volume is trending up with low volatility.

Generated by AI

Community

Of the messages about BIIB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	4.5%	42.77%	60.42%
Newcomers	—	95.5%	57.23%	39.58%

Regulars· Jul 29

Biogen's Q2 2026 revenue of $2.74B beat estimates, with a 3% YoY increase, and growth portfolio revenue of $1.06B rising 24% YoY.
The company's adjusted EPS of $3.60 was lower than the previous year, due to higher expenses, but still beat estimates.
Biogen's CEO noted that the company has what it needs to grow, and is easing off acquisitions for a while, focusing on its growth portfolio.

Newcomers· May 18

The newcomer is primarily focused on NovaRed Mining, highlighting stronger copper grades and limited historical exploration, which has changed their view on the asset.
The newcomer is impressed by the strong revenue numbers and growth of $NXXT, with a yearly revenue of 81.8M and +195% yearly growth, making it a bullish setup.
The newcomer is discussing Biogen's success with Leqembi Alzheimer's, with Goldman Sachs raising Biogen's stock target, and mentioning the asset's recent rough stretch.

Generated by AI

Biogen

Social

Aug 25

Bullish· Mar 31

Bearish· Feb 13

Earnings· Jul 29

Analysts· Aug 7

Announcements· Jun 18

Controversies· Sep 27

Technical Analysis· Sep 29

Regulars· Jul 29

Newcomers· May 18

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data

Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?

Biogen stock hits 52-week high at 225.88 USD

Biogen: Growth Is Back, But It Came At A Price (NASDAQ:BIIB)

Is Biogen Stock Outperforming the S&P 500?

Also Discussed

Biogen Inc

Company Information

Location

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data

Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?

Biogen stock hits 52-week high at 225.88 USD

Biogen: Growth Is Back, But It Came At A Price (NASDAQ:BIIB)

Is Biogen Stock Outperforming the S&P 500?

Also Discussed

Social

Aug 25

Bullish· Mar 31

Bearish· Feb 13

Earnings· Jul 29

Analysts· Aug 7

Announcements· Jun 18

Controversies· Sep 27

Technical Analysis· Sep 29

Regulars· Jul 29

Newcomers· May 18